US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Articles published by NRx Pharmaceuticals, Inc.

News headline image
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers NRXP